Image-based dosimetry for 225 Ac-PSMA-I&T therapy using quantitative SPECT
- PDF / 303,115 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 51 Downloads / 214 Views
IMAGE OF THE MONTH
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT A. Gosewisch 1 & M. Schleske 1 & F. J. Gildehaus 1 & I. Berg 1 & L. Kaiser 1 & J. Brosch 1 & P. Bartenstein 1 & A. Todica 1 & H. Ilhan 1 & G. Böning 1 Received: 13 June 2020 / Accepted: 31 August 2020 # The Author(s) 2020
Targeted alpha therapy (TAT) using 225Ac-PSMA ligands is a promising therapy option for advanced metastatic castration-resistant prostate cancer (mCRPC) [1]. The 225Ac decay chain shows a noticeable gamma emission (440 keV, 25.9%; 218 keV, 11.4%). However, recommended low therapeutic activities (4–8 MBq) limit the clinical applicability of SPECT [2], although initial attempts for 225Ac imaging exist [3, 4]. Particularly quantitative SPECT is a vital tool to assess dosimetry and therapy response. While the 218-keV-peak is characterized by a lower branching ratio and a higher scatter fraction, SPECT imaging of high-energy gammas such as 440 keV causes a complex detector point spread function (PSF) [5]. In this study, we would like to demonstrate the general feasibility of image-based dosimetry for 225Ac radionuclide therapy using quantitative 225Ac SPECT. For a mCRPC patient (65 years), imaging of the abdomen was performed 24 h p. i. of 8.1 MBq 225Ac-PSMA-I&T on a Siemens Symbia Intevo T16 SPECT/CT (440 keV (width, 20%), lower adjacent window (width, 10%),
This article is part of the Topical Collection on Image of the month. * H. Ilhan [email protected] 1
Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
HEGP collimator, 16 projections/head, 128 × 128 pixel, 210 s/projection). Reconstruction was carried out via a MAP algorithm (30i1s) [6], including CT-based attenuation and dual-energy-window scatter correction and a simulated distance-dependent 2D PSF model (SIMIND). Final absorbed dose assessment was performed by combining the single 225Ac image with the effective half-life information determined from a previous 177Lu-PSMAI&T imaging sequence [7]. This resulted in an absorbed dose of 0.18 and 0.17 SvRBE = 5/MBq for the left and right kidney, respectively, compared with 0.27 and 0.24 Gy/GBq for the preceding 177Lu cycle (6.2 GBq). A comparison with the pre-therapy 18 F-PSMA-I&T PET/CT demonstrates that 225Ac SPECT imaging for this patient was able to locate a small lesion in the right hip. The 225Ac-absorbed dose was determined as 0.26 SvRBE = 5/MBq, compared with 0.35 Gy/GBq for 177LuPSMA-I&T. Our analysis demonstrates the feasibility of dosimetry for 225 Ac-PSMA-I&T, which provides further insights into theranostic approaches using TAT in mCRPC patients.
Eur J Nucl Med Mol Imaging
Funding Open Access funding enabled and organized by Projekt DEAL.
References
Compliance with ethical standards
1.
All procedures performed in this study involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard
Data Loading...
